Physician profile
Mohammed Dawood
NPI 1174589576
$522.15
in general payments reported to CMS, 2019-2025
10 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $17.38 · 2024: $3.08 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.45 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $117.45 | 2025 | Rezdiffra |
| Vifor Pharma, INC. | $75.94 | 2019 | |
| Opko Pharmaceuticals, LLC | $70.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.16 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $63.95 | 2019 | |
| Amgen INC. | $44.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.29 | 2019 | |
| Akebia Therapeutics INC | $20.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.07 | 2019 | |
| Travere Therapeutics, INC. | $4.74 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Dawood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.